Intellia Therapeutics (NTLA) Tops Q3 EPS by 5c

Intellia Therapeutics (NASDAQ: NTLA) reported Q3 EPS of ($1.34), $0.05 better than the analyst estimate of ($1.39). Revenue for the quarter came in at $9.11 million versus the consensus estimate of $8.28 million.

For earnings history and earnings-related data on Intellia Therapeutics (NTLA) click here.

You May Also Be Interested In

• Tesla Crash Into Texas Home Now Under Federal Safety Probe - WSJ
• S&P Global (SPGI) Declares $0.97 Quarterly Dividend; 1% Yield
• Rocket Lab launches U.S. Space Force mission in record 16 hours